{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:39:01Z","timestamp":1762270741472},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1016\/j.bone.2004.10.014","type":"journal-article","created":{"date-parts":[[2005,2,25]],"date-time":"2005-02-25T18:55:31Z","timestamp":1109357731000},"page":"358-364","source":"Crossref","is-referenced-by-count":25,"title":["The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study"],"prefix":"10.1016","volume":"36","author":[{"given":"Jenny Y.Y.","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew Y.Y.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.P.","family":"Ip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie W.C.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2004.10.014_bib1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF01623184","article-title":"Hip fractures in the elderly: a worldwide projection","volume":"2","author":"Cooper","year":"1992","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2004.10.014_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s001980170135","article-title":"The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS)","volume":"12","author":"Lau","year":"2001","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2004.10.014_bib3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/ije\/19.4.1119","article-title":"Hip fracture in Hong Kong and Britain","volume":"19","author":"Lau","year":"1990","journal-title":"Int. J. Epidemiol."},{"issue":"9","key":"10.1016\/j.bone.2004.10.014_bib4","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/jbmr.5650110922","article-title":"Normal ranges for vertebral height ratios and prevalence of vertebral fracture in Hong Kong Chinese: a comparison with American Caucasians","volume":"11","author":"Lau","year":"1996","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2004.10.014_bib5","doi-asserted-by":"crossref","first-page":"M102","DOI":"10.1093\/gerona\/53A.2.M102","article-title":"Impact of chronic diseases on functional limitations in elderly Chinese aged 70 years and over: a cross sectional and longitudinal survey","volume":"53","author":"Woo","year":"1998","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"3","key":"10.1016\/j.bone.2004.10.014_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2004.10.014_bib7","first-page":"177","article-title":"The climacteric of Chinese factory workers","volume":"19","author":"Tang","year":"1994","journal-title":"Mauritas"},{"issue":"14","key":"10.1016\/j.bone.2004.10.014_bib8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.bone.2004.10.014_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effects of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bone.2004.10.014_bib10","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1210\/jc.85.5.1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational double-blind, placebo-controlled trial","volume":"85","author":"Fogelman","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bone.2004.10.014_bib11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","article-title":"Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2004.10.014_bib12","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1172\/JCI113725","article-title":"Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment","volume":"82","author":"Civitelli","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2004.10.014_bib13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s002230001142","article-title":"The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study","volume":"67","author":"Kung","year":"2000","journal-title":"Calcif. Tissue Int."},{"issue":"24","key":"10.1016\/j.bone.2004.10.014_bib14","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures: results from Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.bone.2004.10.014_bib15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jc.87.3.985","article-title":"Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis","volume":"87","author":"Johnell","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2004.10.014_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2004.10.014_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","article-title":"Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy","volume":"17","author":"Sarkar","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.10.014_bib18","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/sim.984","article-title":"A method to assess the proportion of treatment effect explained by a surrogate endpoint","volume":"20","author":"Li","year":"2001","journal-title":"Stat. Med."},{"key":"10.1016\/j.bone.2004.10.014_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jc.85.1.231","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2004.10.014_bib20","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with post-menopausal osteoporosis","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2004.10.014_bib21","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jc.87.4.1586","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2004.10.014_bib22","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","article-title":"Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis","volume":"12","author":"Bjarasson","year":"2001","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2004.10.014_bib23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.10.014_bib24","first-page":"521","article-title":"Reduction in bone turnover predicts hip non-spine and vertebral fracture in alendronate treated women: the fracture intervention trial","volume":"13","author":"Bauer","year":"2002","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2004.10.014_bib25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1359\/JBMR.0301244","article-title":"Biochemical markers of bone metabolism and prediction of fracture in elderly women","volume":"19","author":"Gerdhem","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.10.014_bib26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","article-title":"Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk","volume":"19","author":"Sarkar","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.10.014_bib27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1359\/JBMR.0301231","article-title":"Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate","volume":"19","author":"Seibel","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2004.10.014_bib28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4065\/77.3.262","article-title":"Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials","volume":"77","author":"Taggart","year":"2002","journal-title":"Mayo Clin. Proc."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328204004296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328204004296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T12:51:17Z","timestamp":1548679877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328204004296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S8756328204004296"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2004.10.014","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}